EntreMed Scientists Publish First Report on Tissue Factor Pathway Inhibitor (TFPI) as an Antiangiogenic Agent

Apr 19, 2001, 01:00 ET from EntreMed, Inc.

    ROCKVILLE, Md., April 19 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD)
 today announced the results of a joint effort by its scientists and scientists
 at the American Red Cross.  The study represents the first scientific journal
 publication by EntreMed scientists on Tissue Factor Pathway Inhibitor (TFPI),
 a naturally occurring anticoagulant molecule.  TFPI has a high degree of
 activity against endothelial cells, which are the building blocks of blood
 vessels, resulting in unique antiangiogenic properties.  Coagulation is an
 important component of the metastatic spread of tumors, and by inhibiting both
 coagulation and angiogenesis this new finding uncovers the dual role of TFPI
 as a potential agent for cancer treatment.  Furthermore, EntreMed scientists
 believe that a newly discovered TFPI mechanism offers an important area of
 research for this and other angiogenesis inhibitor product candidates and
 further reinforces the link between blood coagulation and angiogenesis.  The
 article, "Tissue Factor Pathway Inhibitor Inhibits Endothelial Cell
 Proliferation Via Association with the Very Low Density Lipoprotein Receptor,"
 by Hembrough, et al, was published today in the Journal of Biological
 Chemistry (JBC, Vol. 276, No. 15, pp. 12241-12248, 2001).  The paper contains
 the following key findings reported for the first time:
 
      *  tissue factor pathway inhibitor (TFPI), an endogenous anticoagulant
         molecule, specifically inhibits the growth of endothelial cells, which
         makes it an appropriate candidate for development as an antiangiogenic
         drug
 
      *  the very low density lipoprotein (VLDL) receptor was identified as a
         novel receptor for TFPI which mediates TFPI's  inhibitory activity on
         endothelial cells
 
     Dr. Edward R. Gubish, EntreMed's Executive Vice President for Research and
 Development stated, "This work identifies the VLDL receptor as an important
 regulator of endothelial cell growth, provides us with a novel target for the
 development of new antiangiogenic and antitumor drugs, and further expands
 Entremed's efforts into additional areas of angiogenesis research.  TFPI joins
 Endostatin, Angiostatin and Panzem(TM) in the list of naturally occurring
 antiangiogenic molecules that we are developing.  We are currently evaluating
 several potential product candidates that have been identified through
 EntreMed's internal discovery program, including those identified through this
 pivotal research."
     Dr. Dudley Strickland, Chairman of Vascular Biology at the Holland
 Research Laboratory of the American Red Cross, noted, "The discovery that the
 interaction of TFPI with the VLDL receptor regulates endothelial cell growth
 is an unexpected and exciting finding.  This knowledge provides us with a new
 understanding of the fundamental processes underlying many diseases, including
 cancer and atherosclerosis."
     EntreMed, Inc., The Angiogenesis Company(TM), is a clinical-stage
 biopharmaceutical company emphasizing antiangiogenesis therapeutics that
 inhibit abnormal blood vessel growth associated with a broad range of diseases
 such as cancer, blindness and atherosclerosis.  The company's strategy is to
 accelerate development of its core technologies through collaborations and
 sponsored research programs with university medical departments, research
 companies and government laboratories.
     EntreMed's majority owned subsidiary, TheraMed, Inc., develops targeted
 therapeutic products to treat severe and chronic diseases, including cancer,
 serious infections, cardiovascular disease and genetic disorders, based on its
 proprietary technology that uses blood cells for drug and non-viral gene
 delivery.  For further information, please visit the EntreMed web site at
 http://www.entremed.com .
 
     Statements herein that are not descriptions of historical facts are
 forward-looking and subject to risk and uncertainties.  Actual results could
 differ materially from those currently anticipated due to a number of factors,
 including those set forth in the Company's Securities and Exchange Commission
 filings under "Risk Factors," including risks relating to the early stage of
 products under development; uncertainties relating to clinical trials;
 dependence on third parties; future capital needs; and risks relating to the
 commercialization, if any, of the Company's proposed products (such as
 marketing, safety, regulatory, patent, product liability, supply, competition
 and other risks).
 
 

SOURCE EntreMed, Inc.
    ROCKVILLE, Md., April 19 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD)
 today announced the results of a joint effort by its scientists and scientists
 at the American Red Cross.  The study represents the first scientific journal
 publication by EntreMed scientists on Tissue Factor Pathway Inhibitor (TFPI),
 a naturally occurring anticoagulant molecule.  TFPI has a high degree of
 activity against endothelial cells, which are the building blocks of blood
 vessels, resulting in unique antiangiogenic properties.  Coagulation is an
 important component of the metastatic spread of tumors, and by inhibiting both
 coagulation and angiogenesis this new finding uncovers the dual role of TFPI
 as a potential agent for cancer treatment.  Furthermore, EntreMed scientists
 believe that a newly discovered TFPI mechanism offers an important area of
 research for this and other angiogenesis inhibitor product candidates and
 further reinforces the link between blood coagulation and angiogenesis.  The
 article, "Tissue Factor Pathway Inhibitor Inhibits Endothelial Cell
 Proliferation Via Association with the Very Low Density Lipoprotein Receptor,"
 by Hembrough, et al, was published today in the Journal of Biological
 Chemistry (JBC, Vol. 276, No. 15, pp. 12241-12248, 2001).  The paper contains
 the following key findings reported for the first time:
 
      *  tissue factor pathway inhibitor (TFPI), an endogenous anticoagulant
         molecule, specifically inhibits the growth of endothelial cells, which
         makes it an appropriate candidate for development as an antiangiogenic
         drug
 
      *  the very low density lipoprotein (VLDL) receptor was identified as a
         novel receptor for TFPI which mediates TFPI's  inhibitory activity on
         endothelial cells
 
     Dr. Edward R. Gubish, EntreMed's Executive Vice President for Research and
 Development stated, "This work identifies the VLDL receptor as an important
 regulator of endothelial cell growth, provides us with a novel target for the
 development of new antiangiogenic and antitumor drugs, and further expands
 Entremed's efforts into additional areas of angiogenesis research.  TFPI joins
 Endostatin, Angiostatin and Panzem(TM) in the list of naturally occurring
 antiangiogenic molecules that we are developing.  We are currently evaluating
 several potential product candidates that have been identified through
 EntreMed's internal discovery program, including those identified through this
 pivotal research."
     Dr. Dudley Strickland, Chairman of Vascular Biology at the Holland
 Research Laboratory of the American Red Cross, noted, "The discovery that the
 interaction of TFPI with the VLDL receptor regulates endothelial cell growth
 is an unexpected and exciting finding.  This knowledge provides us with a new
 understanding of the fundamental processes underlying many diseases, including
 cancer and atherosclerosis."
     EntreMed, Inc., The Angiogenesis Company(TM), is a clinical-stage
 biopharmaceutical company emphasizing antiangiogenesis therapeutics that
 inhibit abnormal blood vessel growth associated with a broad range of diseases
 such as cancer, blindness and atherosclerosis.  The company's strategy is to
 accelerate development of its core technologies through collaborations and
 sponsored research programs with university medical departments, research
 companies and government laboratories.
     EntreMed's majority owned subsidiary, TheraMed, Inc., develops targeted
 therapeutic products to treat severe and chronic diseases, including cancer,
 serious infections, cardiovascular disease and genetic disorders, based on its
 proprietary technology that uses blood cells for drug and non-viral gene
 delivery.  For further information, please visit the EntreMed web site at
 http://www.entremed.com .
 
     Statements herein that are not descriptions of historical facts are
 forward-looking and subject to risk and uncertainties.  Actual results could
 differ materially from those currently anticipated due to a number of factors,
 including those set forth in the Company's Securities and Exchange Commission
 filings under "Risk Factors," including risks relating to the early stage of
 products under development; uncertainties relating to clinical trials;
 dependence on third parties; future capital needs; and risks relating to the
 commercialization, if any, of the Company's proposed products (such as
 marketing, safety, regulatory, patent, product liability, supply, competition
 and other risks).
 
 SOURCE  EntreMed, Inc.